Literature DB >> 25502509

The significance of persistent fever in the treatment of suspected bacterial infections among inpatients: a prospective cohort study.

A Neuberger1, D Yahav, V Daitch, Y Akayzen, L Farbman, T Avni, L Leibovici, M Paul.   

Abstract

Antibiotic escalations are frequently guided by fever persistence. Unnecessary antibiotic escalation is associated with resistance induction. We examined whether fever persistence is associated with adverse outcomes among medical inpatients with sepsis. In a single-center prospective cohort study, we included consecutive medical inpatients with suspected or documented bacterial infections. Data were collected on days 0, 2, 4, and 30 days from episode onset. We examined the association between fever persistence at 4 days and 30-day mortality on univariate and multivariate analysis. Inappropriate empirical antibiotic treatment (IAET) was defined for patients with microbiologically documented infections (MDIs). Odds ratios (ORs) are presented with 95% confidence intervals (CIs). A total of 1,621 patients were included. Among patients with MDIs, 38/206 (18.4%) given appropriate empiric therapy had continued fever on day 4, compared to 64/231 (27.7%) of patients receiving IAET, OR 0.59, 95% CI 0.37-0.93. Fever persistence was not associated with mortality after adjustment for other risk factors. Among patients with presumed sepsis who did not have MDIs, persistent fever was significantly associated with 30-day mortality on a multivariate analysis, adjusted OR 2.77 (95% CI 1.78-4.31). Other risk factors for mortality included older age, nosocomial infections, malignancy, dyspnea, shock, decreased albumin, and elevated creatinine. For patients with MDIs, fever persistence for up to 4 days is a marker of IAET, but is not associated with mortality, and should not, in itself, trigger antibiotic escalation. For patients without MDIs, fever persistence should trigger careful re-evaluation, as it is associated with mortality.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25502509     DOI: 10.1007/s10096-014-2288-3

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  9 in total

Review 1.  Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis.

Authors:  Mical Paul; Vered Shani; Eli Muchtar; Galia Kariv; Eyal Robenshtok; Leonard Leibovici
Journal:  Antimicrob Agents Chemother       Date:  2010-08-23       Impact factor: 5.191

2.  Improving empirical antibiotic treatment using TREAT, a computerized decision support system: cluster randomized trial.

Authors:  Mical Paul; Steen Andreassen; Evelina Tacconelli; Anders D Nielsen; Nadja Almanasreh; Uwe Frank; Roberto Cauda; Leonard Leibovici
Journal:  J Antimicrob Chemother       Date:  2006-09-23       Impact factor: 5.790

3.  CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting.

Authors:  Teresa C Horan; Mary Andrus; Margaret A Dudeck
Journal:  Am J Infect Control       Date:  2008-06       Impact factor: 2.918

4.  De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock.

Authors:  J Garnacho-Montero; A Gutiérrez-Pizarraya; A Escoresca-Ortega; Y Corcia-Palomo; Esperanza Fernández-Delgado; I Herrera-Melero; C Ortiz-Leyba; J A Márquez-Vácaro
Journal:  Intensive Care Med       Date:  2013-09-12       Impact factor: 17.440

5.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.

Authors:  Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard
Journal:  Clin Infect Dis       Date:  2011-02-15       Impact factor: 9.079

6.  A prospective study of fever in the intensive care unit.

Authors:  B Circiumaru; G Baldock; J Cohen
Journal:  Intensive Care Med       Date:  1999-07       Impact factor: 17.440

7.  European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia.

Authors:  Diana Averbuch; Christina Orasch; Catherine Cordonnier; David M Livermore; Malgorzata Mikulska; Claudio Viscoli; Inge C Gyssens; Winfried V Kern; Galina Klyasova; Oscar Marchetti; Dan Engelhard; Murat Akova
Journal:  Haematologica       Date:  2013-12       Impact factor: 9.941

8.  Occurrence and outcome of fever in critically ill adults.

Authors:  Kevin B Laupland; Reza Shahpori; Andrew W Kirkpatrick; Terry Ross; Daniel B Gregson; H Thomas Stelfox
Journal:  Crit Care Med       Date:  2008-05       Impact factor: 7.598

9.  Early use of imipenem/cilastatin and vancomycin followed by de-escalation versus conventional antimicrobials without de-escalation for patients with hospital-acquired pneumonia in a medical ICU: a randomized clinical trial.

Authors:  Jong Wook Kim; Joowon Chung; Sang-Ho Choi; Hang Jea Jang; Sang-Bum Hong; Chae-Man Lim; Younsuck Koh
Journal:  Crit Care       Date:  2012-02-15       Impact factor: 9.097

  9 in total
  2 in total

1.  Fever Is Associated with Reduced, Hypothermia with Increased Mortality in Septic Patients: A Meta-Analysis of Clinical Trials.

Authors:  Zoltan Rumbus; Robert Matics; Peter Hegyi; Csaba Zsiboras; Imre Szabo; Anita Illes; Erika Petervari; Marta Balasko; Katalin Marta; Alexandra Miko; Andrea Parniczky; Judit Tenk; Ildiko Rostas; Margit Solymar; Andras Garami
Journal:  PLoS One       Date:  2017-01-12       Impact factor: 3.240

2.  Sending repeat cultures: is there a role in the management of bacteremic episodes? (SCRIBE study).

Authors:  J Brad Wiggers; Wei Xiong; Nick Daneman
Journal:  BMC Infect Dis       Date:  2016-06-13       Impact factor: 3.090

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.